MAPK14 and early-onset autosomal dominant Alzheimer disease: This provides the first in vivo demonstration of the effects of selective reduction of MAPK14 activity on autophagy and suggests that therapeutic inhibition of MAPK14 has the potential to address the autophagic defect in Alzheimer disease.